效价很重要:他汀强度在调节年龄相关性黄斑变性风险中的作用
该回顾性临床队列研究利用美国协作网络电子健康记录,纳入2014至2024年40岁及以上2型糖尿病合并血脂异常且有至少一次眼科就诊的成人,经倾向评分匹配后共20282例,评估他汀强度与年龄相关性黄斑变性(AMD)风险的关联。结果显示中强度和高强度他汀与复合AMD风险降低相关,低强度他汀未显示此关联,所有强度他汀均与全因死亡率降低相关。
要点
- 中强度他汀在所有随访时间点与复合AMD和渗出性AMD风险降低相关。
- 高强度他汀与3年和5年时复合AMD风险降低相关,低强度他汀未显示与AMD风险降低相关。
- 所有强度他汀均与全因死亡率降低相关。
核心结论
- 在2型糖尿病合并血脂异常患者中,中强度和高强度他汀治疗与AMD风险降低相关,低强度他汀未显示此关联。
- 原文结论指出需要进一步研究来确认这些发现并阐明潜在机制。
研究设计与样本
- 回顾性临床队列研究,使用美国协作网络去标识电子健康记录。
- 纳入2014至2024年40岁及以上2型糖尿病、血脂异常且至少有一次眼科就诊的成人,排除有肝脏疾病、HIV等混杂条件及既往AMD诊断者。
- 采用倾向评分匹配平衡各他汀强度队列与未治疗对照组间的协变量,匹配后共纳入20282例患者。
主要发现
- 中强度他汀在所有随访时间点与复合AMD风险显著降低相关(HR范围0.49至0.77,原文一处写作95%CI 0.55-0.91,另一处写作95%CI 0.60-0.98)。
- 中强度他汀在所有随访时间点与渗出性AMD风险显著降低相关(HR范围0.19至0.62,原文一处写作95%CI 0.06-0.054,另一处写作95%CI 0.40-0.96)。
- 所有他汀强度均与全因死亡率降低相关。
关键数值与推荐
- 高强度他汀治疗定义为瑞舒伐他汀20-40 mg或阿托伐他汀40-80 mg。
- 中强度他汀治疗定义为瑞舒伐他汀5 mg、10 mg,辛伐他汀20 mg、40 mg,氟伐他汀80 mg,普伐他汀40 mg、80 mg,洛伐他汀40 mg,阿托伐他汀10 mg、20 mg,或匹伐他汀1 mg、2 mg、4 mg。
- 低强度他汀治疗定义为辛伐他汀5-10 mg,普伐他汀10-20 mg,洛伐他汀10-20 mg,或氟伐他汀20-40 mg。
- 主要结局指标为索引事件后6个月、1年、3年和5年的复合AMD(非渗出性和渗出性)、非渗出性AMD、渗出性AMD及全因死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进一步研究来确认这些发现并阐明潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Age-related macular degeneration (AMD) is a leading cause of vision loss. Statins, primarily used for cardiovascular disease prevention, may have pleiotropic effects on AMD, but existing evidence is inconclusive. This study investigated the association between statin intensity (high, moderate, low) and the risk of AMD in patients with type 2 diabetes and dyslipidemia. DESIGN: A retrospective clinical cohort study using de-identified electronic health records from the US Collaborative Network. METHODS: Adults aged 40 years or older with type 2 diabetes, dyslipidemia, and at least 1 ophthalmologic visit were included from 2014 to 2024 Patients with confounding conditions (liver disease, HIV, etc.) and prior AMD diagnoses were excluded. Propensity score matching was used to balance covariates between statin intensity cohorts and a treatment-naïve control group. Intensity groups included: high-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg), high-intensity-naïve, medium-intensity statin therapy (rosuvastatin [5 mg, 10 mg], simvastatin [20 mg, 40 mg], fluvastatin [80 mg], pravastatin [40 mg, 80 mg], lovastatin [40 mg], atorvastatin [10 mg, 20 mg], or pitavastatin [1 mg, 2 mg, 4 mg]), and low-intensity statin therapy (simvastatin 5-10 mg, pravastatin 10-20 mg, lovastatin 10-20 mg, or fluvastatin 20-40 mg). MAIN OUTCOME MEASURES: Incidence of combined AMD (nonexudative and exudative), nonexudative AMD, exudative AMD, and all-cause mortality at 6 months, 1 year, 3 years, and 5 years after the index event. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazard regression models. RESULTS: After matching, a total of 20 282 patients were included. High-intensity statin use was associated with a reduced risk of combined AMD at 3 and 5 years (HR: 0.74 (95% CI: 0.57-094) and 0.79 (95% CI: 0.62-0.98), respectively). Medium-intensity statin therapy was associated with a significantly lower risk of combined AMD (HR range: 0.49 [95% CI 0.55-0.91] to 0.77 [95% CI: 0.60-0.98]) and exudative AMD (HR range: 0.19 [0.06-0.054] to 0.62 [95% CI: 0.40-0.96]) at all follow-up points. All statin intensities were associated with reduced all-cause mortality. CONCLUSIONS: In this study of patients with type 2 diabetes and dyslipidemia, medium- and high-intensity, but not low-intensity, statin therapies were associated with a reduced risk of AMD. Further research is needed to confirm these findings and elucidate the underlying mechanisms.
引用
- Hussain ZS, Chauhan MZ, Muayad J, et al. Potency Matters: The Role of Statin Intensity in Modulating Risk for Age-Related Macular Degeneration. Am J Ophthalmol. 2025. PMID: 40829697. doi:10.1016/j.ajo.2025.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。